Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598209 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL119565 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30802551 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29367497 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29355082 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29624621 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| Fluoride SCHEMBL7155195 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30562127 | 0.96 | MDM4 (0.53) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29400671 | 0.92 | MDM4 (0.52) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL9072218 | 0.91 | MDM4 (0.50) | MDM4TP53CASP3MDM2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192295-A | Neurostatin cyclic peptide and preparation method and application thereof | 西北师范大学 | 2024-12-27 | — | — | CN | claimed |
| CN-118873460-A | Preparation method of antioxidant face cream | 江西御美化妆品有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-117924414-A | Compound for promoting Abeta clearance and preparation method and application thereof | 中山大学 | 2024-04-26 | — | — | CN | claimed |
| WO-2024017317-A1 | HER2 TARGETING PEPTIDE MOLECULE AND USE THEREOF | 中国科学院上海药物研究所 | 2024-01-25 | — | — | WO | claimed |
| CN-114380880-B | Fmoc-amino acid modified 20 (S) -protopanoxadiol derivative and preparation method and application thereof | 吉林大学 | 2023-06-23 | — | — | CN | claimed |
| CN-115232195-A | Oligopeptide two-dimensional nanomaterial and application thereof | 忻州师范学院 | 2022-10-25 | — | — | CN | claimed |
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2021-11-23 | — | — | US | claimed |
| CN-109651243-B | Serine-containing peptoid compound and preparation method and application thereof | 西安交通大学 | 2020-05-22 | — | — | CN | claimed |
| CN-109265370-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-serine | 四川什邡市三高生化实业有限公司 | 2019-01-25 | — | — | CN | claimed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4590423-A1 | METHODS AND PLATFORM FOR CHEMICAL SYNTHESIS | The University Court Of The University Of Glasgow (GB) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025131101-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海多米瑞生物技术有限公司 | 2025-06-26 | — | — | WO | disclosed |
| EP-0394318-A1 | POLYMERS AND POLYMER-PEPTIDE CONJUGATES | MEDICAL RESEARCH COUNCIL (GB) | 1990-10-31 | — | — | EP | disclosed |
| WO-1989005305-A1 | POLYMERS AND POLYMER-PEPTIDE CONJUGATES | 3I RESEARCH EXPLOITATION LIMITED (GB) | 1989-06-15 | — | — | WO | disclosed |
| EP-0316495-A1 | Synthetic peptides useful for the detection of aids-related antibodies in human sera | IAF BIOCHEM INTERNATIONAL INC. (CA) | 1989-05-24 | — | — | EP | disclosed |
| EP-0073828-A4 | HIGH PERFORMANCE PEPTIDE SYNTHESIS. | BIORES INC (US) | 1983-11-09 | — | — | EP | disclosed |
| EP-0073828-A1 | HIGH PERFORMANCE PEPTIDE SYNTHESIS | BIORESEARCH INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| WO-1982003077-A1 | HIGH PERFORMANCE PEPTIDE SYNTHESIS | BIORESEARCH INC (US) | 1982-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885CASP3 795/4885 |
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | CYP51A1, CYP17A1, CYP11A1 | MDM4 4320/4885TP53 4824/4885CASP3 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.